A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Bristol-Myers Squibb
7 Hills Pharma, LLC
Aulos Bioscience, Inc.
3D Medicines
M.D. Anderson Cancer Center
AstraZeneca
Mayo Clinic
Neonc Technologies, Inc.
University of California, Davis
University of California, San Diego
Ocellaris Pharma, Inc.
Inhibrx Biosciences, Inc
Bristol-Myers Squibb
CRISPR Therapeutics
University of Pittsburgh
Dragonfly Therapeutics
Vyriad, Inc.
GI Innovation, Inc.
A2 Biotherapeutics Inc.
Incyte Corporation
Incyte Corporation
NuCana plc
Medicenna Therapeutics, Inc.
Shanghai Public Health Clinical Center
OncoC4, Inc.
Mural Oncology, Inc
Kymab Limited
Portage Biotech
Sarcoma Oncology Research Center, LLC
University Hospital, Antwerp
Nimbus Therapeutics
Simcha IL-18, Inc.
23andMe, Inc.
Salubris Biotherapeutics Inc
NGM Biopharmaceuticals, Inc
GlaxoSmithKline
Eutilex
Novartis
HUYABIO International, LLC.
Rain Oncology Inc
Klus Pharma Inc.
Genmab
4D pharma plc
Western Sydney Local Health District
Calithera Biosciences, Inc
Nektar Therapeutics
Institut Bergonié
Incyte Corporation
Genocea Biosciences, Inc.
Incyte Corporation